



November 5, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: Notice pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Glenmark Pharmaceuticals Inc., USA ("Glenmark") hereby notifies the Vermont Attorney General of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

NDC Number	Product Description	Date of Commercial Availability	Wholesale Acquisition Cost (As of date of commercial availability)
68462-0317-32	Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)	November 4, 2019	\$ 1,745.15